BIV reporter Tyler Orton discusses the U.S. government's plans to buy a COVID-19 therapeutic developed in part by Vancouver's AbCellera. Then, he dives into why BBTV went public amid the pandemic, raising $172 million in the process.
BIV reporter Tyler Orton discusses the U.S. government's plans to buy a COVID-19 therapeutic developed in part by Vancouver's AbCellera. Then, he dives into why BBTV went public amid the pandemic, raising $172 million in the process.